[Reference values for serum transferrin in newborn infants and children].
Explore the source record for details and available documents.
Adolescent↗
Biomedical subjects
M Farnier
Publications and source records attributed to M Farnier.
Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study.
This study examined the action of cerivastatin, a new statin, in subjects with primary hypercholesterolaemia. The effects of two oral doses of cerivastatin (400 micrograms/day or 300 micrograms/day) were compared with placebo in 349 patients using a multicentre, randomized, double-blind, placebo-controlled study design. Cerivastatin treatment lasted 8 weeks and produced significant reductions in low density lipoprotein-cholesterol (LDL-C) levels from baseline compared with placebo. The reduction in LDL-C was significantly greater with 400 micrograms than with 300 micrograms cerivastatin. When responder rates were examined, the higher (400 micrograms/day) cerivastatin dose was found to be more effective in producing larger (> 40%) reductions in LDL-C levels. Cerivastatin treatment was well tolerated. Only two withdrawals due to adverse events during active treatment occurred, neither of which was considered to be due to the study medication. In addition, no clinically relevant increases in the levels of creatine phosphokinase and hepatic transaminases (alanine transaminase and aspartate transaminase) compared with placebo were seen in this study. In conclusion, cerivastatin treatment produced a significant lowering of LDL-C levels, with the higher dose providing the greatest benefit.
Administration, Oral↗
[Hyperlipidemia in the elderly].
UNLABELLED: THE ELDERLY SUBJECT: Cardiovascular prevention trials have clearly established the beneficial effect of lipid-lowering drugs, basically statins, for adults, and in particular for adult males. There has not however been any study specifically analyzing prevention in the elderly. In addition, the relationships between high cholesterol level and cardiovascular risk in the elderly subject are complex and require specific adaptation with markers of poor health status. PREVENTIVE MEASURES: Even though the relationship between elevated total cholesterol or LDL-cholesterol and cardiovascular risk is difficult to demonstrate in the elderly, analyses of subpopulations are beginning to show evidence that a lipid-lowering treatment can have a beneficial preventive effect in the elderly. Other research avenues also point to perspectives for stroke prevention or reduced risk of dementia in patients treated with statins. RECOMMENDATIONS: Until the results of ongoing clinical trials become available, recommendations for therapeutic strategies in the elderly are basically founded on clinical experience in light of current evidence. It is reasonable to recommend a lipid-lowering regimen for secondary prevention and to continue treatment beyond 70 years for primary prevention if the patient's overall cardiovascular risk warrants prevention. But, on the basis of current evidence, there is no rationale for recommending a large screening of hypercholesterolemia in primary prevention in subjects over 70 years of age. Likewise, taking into account associated disease states and the increased risk of drug interactions, primary prevention regimens cannot be recommended except for elderly patients with a high overall cardiovascular risk.
Aged↗
Influence of obesity and hypertriglyceridaemia on the low HDL2-cholesterol level and on its relationship with prevalence of atherosclerosis in type 2 diabetes.
High density lipoprotein subfraction 2 (HDL1)-cholesterol level is usually decreased in Type 2 (non-insulin-dependent) diabetes. A study was carried out in 251 Type 2 diabetic patients (106 males [M], 145 females [F]) and in 120 non diabetic controls in order to determine the influence of hypertriglyceridaemia and obesity on the HDL2-cholesterol level and to analyse the relationship between HDL2-cholesterol level and atherosclerosis (coronary heart disease, peripheral atherosclerosis or cerebral vascular disease), in Type 2 diabetes. Influence of hypertriglyceridaemia and obesity on HDL2-cholesterol level was studied by comparing the mean values of HDL2-cholesterol between diabetics and controls, after controlling for hypertriglyceridaemia and obesity, and by a multiple linear regression test. A stepwise logistic regression was performed to analyse the association between the prevalence of atherosclerosis and several variables: age, duration of diabetes, hypertension, cigarette smoking, body mass index, mean glycaemia, total cholesterol, triglyceride, HDL-cholesterol, HDL2-cholesterol and HDL3-cholesterol levels. In both men and women, when both of the factors (hypertriglyceridaemia and obesity) were present of when only one was, HDL2-cholesterol level was significantly lower in the diabetic population, compared with controls. But when obesity and hypertriglyceridaemia were absent, HDL2-cholesterol level, in the diabetic population, was not significantly different from controls (M: 17.9 +/- 13.3 vs 20.5 +/- 13.8 mg/dl: NS; F: 30.1 +/- 21.5 vs 27.6 +/- 14.2 mg/dl: NS).(ABSTRACT TRUNCATED AT 250 WORDS)
Adult↗